Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tommaso Guerra
Observed name:
T. Guerra
Institutions:
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari,
University of Bari Aldo Moro
Observed institutions:
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari,
University of Bari Aldo Moro
ORCID:
0000-0002-5248-5981
Observed ORCID:
0000-0002-5248-5981
OpenAlex ID:
A5024087119
Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
2021
·
Alessandro Introna
, Francesca Caputo
, et al.
·
Clinical Neurology and Neurosurgery
·
83
PDF
Multiple Sclerosis Progression and Relapse Activity in Children
2023
·
Pietro Iaffaldano
, Emilio Portaccio
, et al.
·
JAMA Neurology
·
59
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
2020
·
Luca Bollo
, Tommaso Guerra
, et al.
·
Journal of the Neurological Sciences
·
38
PDF
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis
2024
·
Pietro Iaffaldano
, Giuseppe Lucisano
, et al.
·
Annals of Clinical and Translational Neurology
·
25
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis
2024
·
Marta Simone
, Giuseppe Lucisano
, et al.
·
Journal of Neurology
·
21
PDF
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients
2022
·
Damiano Paolicelli
, Maddalena Ruggieri
, et al.
·
Brain Sciences
·
21
PDF
Early Intensive Versus Escalation Approach: Ten‐Year Impact on Disability in Relapsing Multiple Sclerosis
2025
·
Pietro Iaffaldano
, Giuseppe Lucisano
, et al.
·
Annals of Clinical and Translational Neurology
·
19
PDF
The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies Evaluation
2025
·
Tommaso Guerra
, Massimiliano Copetti
, et al.
·
Neurology Neuroimmunology & Neuroinflammation
·
18
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
2021
·
Tommaso Guerra
, Francesca Caputo
, et al.
·
Neurological Sciences
·
17
PDF
A Window into New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current Perspective
2025
·
Tommaso Guerra
, Pietro Iaffaldano
·
International Journal of Molecular Sciences
·
14
PDF
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register
2023
·
Paola Mosconi
, Tommaso Guerra
, et al.
·
Neurological Sciences
·
14
PDF
Refining Prognostic Factors in Adult-Onset Multiple Sclerosis: A Narrative Review of Current Insights
2025
·
Tommaso Guerra
, Massimiliano Copetti
, et al.
·
International Journal of Molecular Sciences
·
13
PDF
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing
2024
·
A. Manni
, F. Oggiano
, et al.
·
Journal of the Neurological Sciences
·
13
PDF
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register
2022
·
Pietro Iaffaldano
, Giuseppe Lucisano
, et al.
·
Multiple Sclerosis Journal
·
13
PDF
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience
2022
·
Tommaso Guerra
, Antonella Pipoli
, et al.
·
Neurological Sciences
·
12
PDF
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration
2021
·
D. Ferraro
, P. Iaffaldano
, et al.
·
Journal of Neurology
·
12
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry
2023
·
Pietro Iaffaldano
, Giuseppe Lucisano
, et al.
·
Journal of Neurology
·
10
Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: A case report
2025
·
Tommaso Guerra
, Damiano Paolicelli
, et al.
·
Multiple Sclerosis Journal
·
6
Long-Term Evaluation of Effectiveness and Immunological Implications of Ocrelizumab in a Real-World Cohort
2025
·
Tommaso Guerra
, Francesca Caputo
, et al.
·
Drugs - Real World Outcomes
·
5
Guillain‐Barré syndrome associated with inappropriate secretion of antidiuretic hormone following SARS‐CoV‐2 infection: A case‐report
2021
·
Carlo Santoro
, Tommaso Guerra
, et al.
·
Clinical Case Reports
·
4
PDF
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series
2024
·
Antonella Bianco
, Tommaso Guerra
, et al.
·
Clinical Neurology and Neurosurgery
·
3
Dengue fever in a multiple sclerosis patient taking Ocrelizumab
2021
·
Tommaso Guerra
, Luca Bollo
, et al.
·
Multiple Sclerosis Journal
·
3
Health Literacy and Unmet Needs in Patients With Multiple Sclerosis: A Cross‐Sectional Study
2026
·
Francesco Pastore
, Barbara Forastefano
, et al.
·
Journal of Clinical Nursing
·
2
Refining predictors of long-term NEDA-3 status in relapsing-remitting multiple sclerosis: insights from real-world data
2026
·
Tommaso Guerra
, Antonella Bianco
, et al.
·
Neurological Sciences
·
2
PDF
Validation of generative artificial intelligence techniques for synthetic data generation in multiple sclerosis research: A comparison with real-world evidence from the Italian multiple sclerosis registry
2026
·
Pietro Iaffaldano
, Saverio D’Amico
, et al.
·
Multiple Sclerosis Journal
·
1
PDF
Show more works
View as search
Works count:
37
Citation count:
431
H-index:
13
I10-index:
17
Year
Topic
Type